Global Mice Model Market By By Model Type (Genetically Modified Mice (Transgenic Mice, Knockout Mice and Knock-in Mice), Outbred Mice (Swiss Webster Mice & CD-1 Mice), Inbred Mice, (C57BL/6 Mice & BALB/c Mice) and Hybrid Mice (F1 Hybrid Mice & F2 Hybrid Mice)), By Service (Breeding Services, Cryopreservation, Rederivation Services, Quarantine Services and Other Services), By Technology (CRISPR/Cas9, Embryonic Stem Cell Injection, Nuclear Transfer, Microinjection, Physiological Monitoring and Others), By Application (Oncology, Neurology, Cardiovascular Diseases, Immunology, Metabolic Diseases, Toxicology Study, Infectious Diseases and Others), By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, Contract Research Organizations (CROs), and Hospitals & Clinics), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Mice Model Market size is expected to be worth around US$ 3.27 Billion by 2034 from US$ 1.68 Billion in 2024, growing at a CAGR of 6.9% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 39.4% share with a revenue of US$ 661.9 Billion.

The steady demand in the market is driven by oncology, immunology, and rare-disease research, which increasingly relies on genetically engineered strains offering better translational validity. CRISPR/Cas9 remains the dominant technology, rapidly gaining traction as the fastest-growing method, significantly reducing model generation times and costs. North America continues to lead due to concentrated R\&D investments and strong pharmaceutical activity.

However, Asia-Pacific is quickly narrowing the gap, with China, Japan, and South Korea heavily investing in local breeding infrastructure. Contract research organizations (CROs) are capturing a larger share of outsourced studies, while the significance of humanized immune system and patient-derived xenograft (PDX) libraries is rising for immuno-oncology validation. While regulatory pressures for alternative methods present challenges, they also encourage model developers to create higher-fidelity, ethically refined lines.

Many diseases can be modeled by modifying specific genes crucial to normal biological processes. The Jackson Laboratory provides thousands of disease models, either spontaneously developed in their production colonies or genetically engineered, available for research purposes. For instance, in June 2025, the Jackson Laboratory’s announced that they have developed humanized mice which provide an advanced solution by closely mimicking human physiology and pathology. These sophisticated models enhance the reliability, accuracy, and predictability of research, particularly in areas such as immuno-oncology, infectious diseases, and autoimmunity.

Mice offer several practical advantages: they are small, have a short generation time, and possess an accelerated lifespan (one mouse year equals roughly 30 human years), which helps keep the costs, space requirements, and time needed for research manageable. One of the most significant benefits of using mice is the ability to genetically engineer new strains, including those that can host patient-derived tumors, carry specific gene mutations, or even possess a human immune system.

Key Takeaways

• In 2024, the market for Mice Model generated a revenue of US$ 1.68 billion, with a CAGR of 6.9%, and is expected to reach US$ 3.27 billion by the year 2034.
• The Model Type segment is divided into Genetically Modified Mice, Outbred Mice, Inbred Mice, and Hybrid Mice with Genetically Modified Mice taking the lead in 2023 with a market share of 38.5%.
• By Service, the market is bifurcated into Breeding Services, Cryopreservation, Rederivation Services, Quarantine Services, and Other Services, with Breeding Services leading the market with 47.2% of market share.
• Furthermore, concerning the Technology segment, the market is segregated into CRISPR/Cas9, Embryonic Stem Cell Injection, Nuclear Transfer, Microinjection, Physiological Monitoring, and Others. The CRISPR/Cas9stands out as the dominant segment, holding the largest revenue share of 46.9% in the Mice Model market.
• Considering Application, the market is classified into Oncology, Neurology, Cardiovascular Diseases, Immunology, Metabolic Diseases, Toxicology Study, Infectious Diseases, and Others, with Oncology taking the lead in 2024 with 32.5% market share.
• Additionaly, by end user the market is bifurcated into Pharmaceutical & Biotechnology Companies, Research Laboratories, Contract Research Organizations (CROs), and Hospitals & Clinics, with Pharmaceutical & Biotechnology Companies taking the dominatin gposition in 2024 with 41.6% market share.
• North America led the market by securing a market share of 39.4% in 2023.

Model Type Analysis

Genetically Modified Mice dominated the market which accounted for over 38.5% market share in 2024. These mice play a crucial role in biomedical research and drug discovery due to their ability to mimic human diseases at a genetic level. Genetically modified mice, including transgenic, knockout, and knock-in mice, are specifically designed to carry alterations in their genetic makeup, making them invaluable tools for studying complex diseases such as cancer, diabetes, and neurological disorders. The increasing prevalence of chronic diseases and the rising demand for personalized medicine are driving the growth of this segment.

Genetically modified mice allow researchers to investigate the genetic basis of diseases, test new drug therapies, and explore gene therapy approaches. The CRISPR-Cas9 technology, which enables precise gene editing, has further boosted the demand for genetically modified mice by making it more efficient and cost-effective to create custom models. Companies like Charles River Laboratories and The Jackson Laboratory are leading this trend, providing a range of genetically modified mice tailored to the needs of researchers.

For instance, in November 2024, Taconic Biosciences, a leader in genetically engineered rodent models and services, has announced the expansion of its mouse model production and colony management services with the opening of a new facility on the U.S. West Coast. Located in Seattle, WA, the new facility will enhance the availability of both off-the-shelf standard strains and advanced genetically modified models, offering increased delivery frequency and reduced transit times.

Service Analysis

Breeding services accounted for th largest market share in 2024 of 47.2% as these services are critical for generating high-quality, genetically uniform mice models that are essential for research and drug development. These services ensure the consistent production of inbred, outbred, and genetically modified mice, which are used across a wide range of biomedical applications, including genetic research, drug discovery, and disease modeling. With the increasing demand for genetically modified mice, breeding services play an essential role in maintaining the required genetic integrity and health of the mice.

They also support the production of large quantities of specific mouse strains, which is crucial for studies requiring a large sample size or continuous research. For example, in February 2025, Researchers at the Canberra breeding facility are working to help bring smoky mice, a native species, back from the brink of extinction. Unlike the more prolific common mice, smoky mice are complex social animals that do not breed in large numbers, as evidenced by their declining population.

Technology Analysis

CRISPR/Cas9 technology has revolutionized the genetic modification of mice by enabling precise, targeted changes to their DNA which accounted for 46.9% share in the global market. This gene-editing tool allows researchers to create genetically modified mice with high accuracy and efficiency, facilitating the study of specific genes involved in diseases such as cancer, neurological disorders, and metabolic conditions.

The popularity of CRISPR/Cas9 lies in its ability to make quick, cost-effective alterations to the genome, drastically reducing the time and expense traditionally associated with developing genetically modified mice. This has led to widespread adoption in both academic research and pharmaceutical development. With the increasing demand for tailored disease models and personalized medicine, CRISPR/Cas9 provides a scalable solution for creating custom mice models that closely mimic human genetic conditions.

Application Analysis

The dominating segment in the Mice Model Market by application is Oncology which covered 32.5% of the total market. Cancer research has been a primary focus for biomedical research, and mice models play a crucial role in studying the mechanisms of cancer and developing new therapies. Genetically modified mice, in particular, are widely used to mimic various forms of cancer, enabling researchers to better understand tumor progression, metastasis, and the efficacy of potential cancer treatments.

The increasing prevalence of cancer globally, coupled with the rising demand for more effective cancer therapies, has led to a surge in the use of mice models in oncology. Researchers rely on these models to test new drugs, study tumor biology, and explore immuno-oncology treatments, which have seen significant advancements in recent years. Mice models also facilitate the development of personalized cancer therapies, aligning with the growing trend of precision medicine.

Companies like Charles River Laboratories and Taconic Biosciences provide specialized mice models tailored to cancer research. As oncology remains a dominant field of study, the demand for mice models in cancer research is expected to continue growing, cementing oncology as the dominant application in the mice model market.

End User Analysis

The dominating segment in the Mice Model Market by end user is Pharmaceutical & Biotechnology Companies with a 41.6% market share. These companies are the primary consumers of mice models, as they rely heavily on animal models for drug discovery, preclinical testing, and disease modeling. Mice models are essential in evaluating the safety, efficacy, and pharmacodynamics of new drugs and therapies, making them a cornerstone of the pharmaceutical and biotechnology industries.

As pharmaceutical and biotechnology companies continue to develop novel drugs, biologics, and gene therapies, the demand for high-quality, genetically modified, and disease-specific mice models has risen. This segment’s growth is driven by the increasing complexity of diseases, such as cancer, neurological disorders, and genetic diseases, which require highly specialized animal models to accurately replicate human conditions for testing potential therapies.

Key Market Segments

By Model Type

• Genetically Modified Mice
  • Transgenic Mice
  • Knockout Mice
  • Knock-in Mice
• Outbred Mice
  • Swiss Webster Mice
  • CD-1 Mice
• Inbred Mice
  • C57BL/6 Mice
  • BALB/c Mice
• Hybrid Mice
  • F1 Hybrid Mice
  • F2 Hybrid Mice

By Service

• Breeding Services
• Cryopreservation
• Rederivation Services
• Quarantine Services
• Other Services

By Technology

• CRISPR/Cas9
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Microinjection
• Physiological Monitoring
• Others

By Application

• Oncology
• Neurology
• Cardiovascular Diseases
• Immunology
• Metabolic Diseases
• Toxicology Study
• Infectious Diseases
• Others

By By End User

• Pharmaceutical & Biotechnology Companies
• Research Laboratories
• Contract Research Organizations (CROs)
• Hospitals & Clinics

Drivers

Growing Demand for Personalized Medicine

The increasing shift towards personalized medicine is a significant driver for the mice model market. Personalized medicine tailors treatments based on individual genetic profiles, making the need for animal models crucial in understanding disease mechanisms and treatment responses at a molecular level. Mice models are often used in genetic studies to simulate human conditions, providing valuable insights for the development of personalized therapies.

For instance, genetically modified mice are utilized to create models for specific genetic conditions, allowing researchers to test how targeted treatments can address particular genetic variations. This approach is gaining traction, as it helps identify the most effective treatment strategies for individuals, thereby enhancing the precision of healthcare. The growing adoption of technologies like CRISPR-Cas9 for gene editing and the increasing prevalence of diseases such as cancer and genetic disorders have further fueled this demand.

For instance, in January 2022, Sanofi and Exscientia announced a pioneering research collaboration and license agreement aimed at developing up to 15 novel small molecule candidates in the fields of oncology and immunology. The collaboration will leverage Exscientia’s comprehensive AI-driven platform, which utilizes real patient samples. This innovative approach will test AI-designed drug candidates against patient tissue models, potentially offering significantly greater accuracy compared to traditional methods, such as mouse models.

Restraints

Ethical Concerns and Regulatory Challenges

Ethical concerns and stringent regulatory frameworks around the use of animal models, particularly mice, are major restraints for the growth of the mice model market. The growing societal demand for ethical standards in research has led to a rise in animal rights movements, questioning the morality of using animals in experiments. As a result, various countries have implemented stricter regulations to ensure the humane treatment of laboratory animals.

These regulations, while crucial for animal welfare, can slow down research and increase the costs associated with obtaining and maintaining animal models. For example, the European Union’s Directive 2010/63/EU mandates that alternatives to animal testing must be considered before using animals, potentially limiting the number of animals available for research. This creates a significant challenge for companies in the mice model market, as they must invest in additional resources to comply with these ethical standards and regulatory requirements.

Opportunities

Advancements in Genetic Engineering and CRISPR Technology

One of the most promising opportunities for the mice model market lies in advancements in genetic engineering and CRISPR technology. The ability to edit genes with precision has revolutionized the creation of genetically modified mice, enabling researchers to develop more accurate disease models. CRISPR-Cas9, a gene-editing tool, allows scientists to introduce or remove specific genes in mice, creating models that closely mimic human diseases. This technology has opened up new avenues for studying complex diseases such as cancer, neurodegenerative diseases, and genetic disorders.

For example, researchers have used CRISPR to create mouse models of Alzheimer’s disease, which are crucial in testing potential treatments. The rapid development of CRISPR-based mice models is expected to reduce the time and cost associated with genetic modifications in animals, making them more accessible to researchers.

In December 2024, Editas Medicine announced a strategic shift towards becoming an in vivo gene editing company, with the goal of achieving human proof of concept within approximately two years. The company successfully demonstrated pre-clinical in vivo proof of concept for high-level HBG1/2 promoter editing and HbF induction in a humanized mouse model, aimed at treating sickle cell disease and beta thalassemia. This was accomplished with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulation.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the Mice Model Market, impacting the availability, demand, and cost of animal models used in research. Economic conditions, such as inflation and recession, can strain research budgets, leading to reduced funding for pharmaceutical and academic research institutions. This directly affects the demand for mice models, especially in developing countries where research funding may be limited. Additionally, economic slowdowns can result in delays or halts in research projects, further reducing the market’s growth.

Geopolitical instability, such as trade wars or regional conflicts, also poses challenges. Restrictions on international trade and tariffs can disrupt the supply chain for mice models, particularly in regions heavily reliant on imports for specialized genetic strains. For example, geopolitical tensions between the U.S. and China can impact the flow of research materials, including genetically modified mice, between these countries.

Moreover, regulatory changes in various regions, driven by macroeconomic and political shifts, can impact the availability and use of animal models. Stricter animal welfare laws and ethical concerns, particularly in Europe, may lead to tighter regulations and higher costs for breeding and maintaining mice models. In contrast, certain countries may relax regulations to foster scientific research, presenting opportunities for growth in those regions.

Latest Trends

Increasing Adoption of 3D Bioprinting in Animal Models

A key trend in the mice model market is the increasing adoption of 3D bioprinting technologies to create more complex and realistic animal models. Traditional mice models have limitations in replicating the full complexity of human diseases, particularly in the areas of tissue architecture and organ interactions. 3D bioprinting, which involves printing cells and tissues layer by layer to create 3D structures, is helping overcome these challenges by providing more accurate models for drug discovery and disease research.

This technology enables the creation of more physiologically relevant models that simulate human-like conditions, which are essential for studying diseases and testing new treatments. For example, researchers are now able to print liver and kidney tissues for use in mice models, making these models more representative of human disease progression.

The growing interest in 3D bioprinting among pharmaceutical companies, universities, and biotech firms is expected to drive demand for more advanced, customizable animal models. In the field of neuronal tissue regeneration, 3D bioprinting holds significant potential. In December 2022, researchers used the micro-SLA technique to fabricate a photocurable resin based on PEG. The resulting device demonstrated controllable handling properties and showed autograft control in a thy-1-YFP-H mouse model after 21 days of implantation. The injury gap in the mouse was 3 mm.

Regional Analysis

North America is leading the Mice Model Market

North American mice model market is poised for continued growth which dominated the global market with 39.4% market share, driven by ongoing advancements in genetic engineering, a strong research ecosystem, and increasing demand for personalized medicine. The region’s leadership in biomedical research and development positions it as a key player in the global mice model market.

In February 2025, a research team led by Professor Jiyue Zhu from the WSU College of Pharmacy and Pharmaceutical Sciences has developed mice with human-like short telomeres, allowing for the study of cellular aging in a way that closely mimics human biology and organ systems. Typically, mice have telomeres that are up to 10 times longer than those of humans. Professor Zhu received US$5 million in grants to further develop this mouse model, which simulates human replicative aging, as well as to explore the potential implications for cancer research.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Key players in the Mice Model market includes Charles River Laboratories International, Inc., The Jackson Laboratory, Envigo (Harlan Laboratories), Taconic Biosciences, Inc., Crown Bioscience, Inc., Jackson ImmunoResearch Laboratories, Inc., Eurofins Scientific, GenOway, Transposagen Biopharmaceuticals, Inc., CedarLane, Pharmaleads, Cytotechnology, Inc., Celerion, Labcorp Drug Development, and Others.

Charles River Laboratories is a leading provider of preclinical and clinical contract research services. In the mice model market, it specializes in offering genetically modified, inbred, and outbred mice for drug discovery, disease research, and safety testing. The company’s services include breeding, quarantine, and testing, supporting global pharmaceutical and biotech companies in advancing their research and development efforts efficiently and ethically. The Jackson Laboratory is a renowned nonprofit research institution specializing in genetics and biomedical research. In the mice model market, it is known for producing high-quality, genetically defined mouse models, including inbred, hybrid, and genetically modified strains. These models are critical for research in cancer, neurology, immunology, and genetic diseases, supporting academic, government, and pharmaceutical research with precision-engineered mouse models for drug discovery and disease modeling.

Market Key Players

• Charles River Laboratories International, Inc.
• The Jackson Laboratory
• Envigo (Harlan Laboratories)
• Taconic Biosciences, Inc.
• Crown Bioscience, Inc.
• Jackson ImmunoResearch Laboratories, Inc.
• Eurofins Scientific
• GenOway
• Transposagen Biopharmaceuticals, Inc.
• CedarLane
• Pharmaleads
• Cytotechnology, Inc.
• Celerion
• Labcorp Drug Development
• Other Prominent Players

Recent Developments

• In March 2025, Colossal Biosciences announced the birth of the Colossal Woolly Mouse mice engineered to express multiple mammoth-like traits that enhance survival in cold climates. By successfully modifying seven genes simultaneously, Colossal’s team created mice with significantly altered coat color, texture, and thickness, closely resembling the core phenotypes of the woolly mammoth.
• In July 2024, scientists at The University of Texas Health Science Center at San Antonio developed a humanized mouse model with a fully functional human immune system and a human-like gut microbiome, capable of mounting specific antibody responses. The goal of this multi-year project was to address the limitations of existing in vivo human models by creating a mouse with a fully developed and operational human immune system.
• In March 2024, AbTherx, a biotechnology company specializing in innovative technologies that accelerate antibody discovery, announced the expanded commercialization of its bispecific and full human diversity antibody discovery technologies. Following a successful initial launch that led to partnerships with top 10 pharmaceutical companies as well as not-for-profit organizations, AbTherx’s Atlas Binary Fixed Light Chain and Full Human Diversity Mice are now available for evaluation by pharmaceutical and biotech companies. These technologies can be accessed through a network of preferred service providers.

Report Scope